Urokinase is a chymotrypsin-like serine protease and an endogenous extrinsic plasminogen activator that is important in conversion of the circulating proenzyme plasminogen into the active serine protease plasmin.1 Urokinase is a single-chain glycoprotein with a molecular weight of 53 kd in the high–molecular-weight form and 33 kd in the low–molecular-weight form.a Urokinase promotes fibrinolysis by catalyzing the cleavage of plasminogen to plasmin.2 Urokinase receptor, a 60- to 65-kd glycer-phosphatidyl–linked glycoprotein, is a membrane-bound protein that binds to uPA to localize degradation of extracellular and basement membranes.3–6 Urokinase-uPAR complexes on cell surfaces have proteolytic, cell migratory, adhesive, and chemotactic effects and participate in extravascular fibrinolysis.7–13
In humans, uPA is produced primarily by renal parenchymal cells and excreted in the urine.14 Secretion of uPA by bovine urothelial cells in vitro has also been described.15 One proposed role of uPA in the urinary tract is to ensure patency throughout its many tubular structures during hemorrhage. The presence of uPAR on cell surface membranes is important, but not necessary, for the activity of uPA in the tissues.16,17 However, in humans, uPA concentration and activity are increased in inflammatory and other pathologic conditions of the urinary tract,15,18 and uPAR on the cell membrane is increased in many neoplastic cell lines and inflammatory processes.19
The purpose of the study reported here was to determine distribution of uPA-like and uPAR-like proteins in urinary tract tissues of healthy dogs.
Materials and Methods
Dogs—Dogs included in this study were chosen on the basis of absence of systemic illness as determined by physical examination, absence of gross pathologic abnormalities in the urinary tract, and absence of histopathologic abnormalities as determined by evaluation of H&E-stained tissue sections from the urinary tract. Dogs were euthanatized for purposes other than this study by IV administration of sodium pentobarbital (120 mg/kg). Dogs were scheduled for euthanasia because of positive results of heartworm antigen tests following a terminal surgical exercises laboratory that did not involve the urinary tract. All procedures were approved by the institutional animal care and use committee.
Specimens—Tissue specimens were collected immediately after euthanasia from kidney, ureter, urinary bladder, urethra, prostate, and testis from 5 sexually intact male dogs; kidney, ureter, urinary bladder, urethra, and prostate from 2 castrated male dogs; and kidney, ureter, urinary bladder, and urethra from 4 sexually intact female dogs. A 2 × 1-cm fullthickness wedge of cortex and medulla was obtained from the middle portion of the kidney. A 2-cm full-thickness section was obtained from the ureter contralateral to that of the kidney specimen. A 2 × 2-cm full-thickness specimen was obtained from the ventral portion of the urinary bladder wall. A 1 × 1-cm wedge was taken from 1 lobe of the prostate. A 2-cm full-thickness section was taken from the prostatic and penile urethra in male dogs. A 2-cm full-thickness section was taken from the midurethra in female dogs. A 2-cm fullthickness wedge was taken from 1 testis. Tissue specimens for morphologic study were immediately snap-frozen in liquid nitrogen. Specimens were stored at −80°C until preparation via formalin fixation and paraffin embedding. Sections (4 μm) were cut and stained with H&E or used for immunohistochemical staining.
Antibodiesmdash;Antibodies used in the study were mouse monoclonal antibody against mouse urokinaseb; mouse monoclonal antibody against human urokinase B-chainc; mouse monoclonal antibody against human urokinase receptor CD 87d; and goat polyclonal peroxidase conjugated anti-mouse IgG.e
SDS-PAGE and western blot analysis—Samples of kidney tissues from all groups of dogs were pooled. Samples of prostate tissue from all male dogs were pooled. Samples of testis tissues from all male intact dogs were pooled. Each pooled tissue sample was manually crushed with a tissue grinderf in radioimmunoprecipitation bufferg at a temperature of 4°C. The resulting tissue lysate was transferred to polypropylene screw-cap microtubesh by use of a pipette and frozen at −20°C for later analysis. The tissue lysates were thawed at room temperature (21°C) prior to SDS-PAGE and western blot analysis.
The SDS-PAGE gel and buffers were prepared as described by Laemmli.20 Tissue lysates were denatured by boiling at 100°C. Four microliters of 4X SDS sample bufferi was added to 20 μL of denatured sample and applied to the SDS gel (10-cm resolving gels of 7.5% acrylamide and 2-cm stacking gels of 4% acrylamide). The samples were subjected to electrophoresis at room temperature at 100 mV for 2 hours or until the dye reached the bottom of the gel. Molecularweight markersj,k were electrophoresed in the first lane beside the samples for identification of the molecular weight of each protein band. Separated proteins were transferred from the SDS gel to polyvinylidene fluoride membranesl for western blot analysis with western transfer buffer. Protein transfer was performed in a western blot apparatusm over 1 hour at 100 mV. The polyvinylidene membrane was incubated with the primary antibody at a 1:1,000 dilution in a 4% nonfat skim milk powder in PBS solution for 16 hours at 4°C. For detection of uPA-like protein, the primary antibodies were mouse anti-mouse uPAb and mouse anti-human uPA.c For detection of uPAR-like protein, the primary antibody was mouse anti-human uPAR antibody.d After incubation, the membrane was washed 3 times (30 minutes each) with the 4% nonfat skim milk solution at room temperature. Following washing, the membrane was incubated at room temperature for 2 hours with goat anti-mouse peroxidaselabeled antibodye at a 1:5,000 dilution. The membrane was again washed 3 times (30 minutes each) with a 1% nonfat skim milk solution. The results were visualized by use of a chemiluminescence reagentn on radiographic film.°
Immunoprecipitation—From each tissue lysate, 200 μL was incubated at room temperature for 2 hours with and without 2 μL of anti-mouse uPAb or anti-human uPA.c The antibody complexes were precipitated by combination with protein A and protein G sepharose beadsp for 1 hour at room temperature. The beads were washed with radioimmunoassay bufferg at 4°C. The antibody-antigen complexes were separated from the beads by boiling at 100°C for 3 minutes. Negative controls contained the tissue lysate alone without the antibody. All immunoprecipitated tissue lysates were then analyzed by use of the SDS-PAGE and western blot analysis protocol outlined in the previous section and compared to the samples that were not immunoprecipitated.
Immunohistochemical analysis—All immunohistochemical stains were performed on paraffin-embedded sections (4 μm). For uPA-like protein detection, an endogenous enzyme block was performed with 0.3% hydrogen peroxide for 10 minutes. Sections were treated with proteinase Kq for 2 minutes for enzyme retrieval followed by protein block with horse serum for 30 minutes. The sections were incubated for 30 minutes with primary mouse anti-mouse uPA antibodyb at a 1:200 dilution. The primary antibody was omitted for negative controls. The secondary antibody system used a mouse systemr (a biotin-free chain polymer-conjugated system with horseradish peroxidase as the chromogen) with incubation for 30 minutes. Sections were incubated for 8 minutes with a peroxidase substrates to allow visualization of the antigen-antibody complexes. Slides were counterstained with hematoxylin for 5 minutes. Intensity of staining was subjectively evaluated by 1 investigator (DP). Cells that stained were identified and described by 1 investigator (DP).
For uPAR-like protein detection, an endogenous enzyme block was performed with 0.3% hydrogen peroxide for 10 minutes. Sections were treated with a high-pH target retrieval systemt at 96°C for 10 minutes for enzyme retrieval, followed by protein block with horse serum for 30 minutes. Sections were incubated for 60 minutes with primary antibody mouse anti-human uPARd at a 1:100 dilution and the same secondary antibody systemr as used previously. Sections were incubated for 8 minutes with peroxidase substrates to allow visualization of the antigen-antibody complexes. Slides were counterstained with hematoxylin for 5 minutes. Intensity of staining was subjectively evaluated by 1 investigator (DBP). Cells that stained were identified and described by 1 investigator (DBP).
Results
uPA-like protein—Western blot analysis resulted in 2 distinct 53-kd– and 33-kd–molecular-weight protein bands (Figure 1). Immunoprecipitation enhanced visualization of the protein bands in the prostate and testis samples. The intensity of the band obtained by use of the kidney lysate was not visually different than that obtained without immunoprecipitation. Without immunoprecipitation, a much stronger band was observed in the kidney than the testis and prostate. Both antibodiesb,c that were used successfully precipitated the urokinase-like antigen.
uPAR-like protein—Western blot analysis with and without immunoprecipitation of kidney, prostate, and testis lysates with human monoclonal uPAR antibody resulted in a distinct protein band at 65 kd. Immunoprecipitation enhanced the visualization of the protein bands in the prostate, kidney, and testis (Figure 2). The mouse anti-human antibodyd successfully precipitated the uPAR-like antigen.
Immunohistochemical staining in kidney—Staining for uPA-like protein in the kidney was consistent across all dogs. Staining was red to red-brown and uniform in the tubular epithelial cells throughout the cortex and medulla (Figure 3). In some sections, cells in the medullary tubules stained more intensely than cells in the proximal convoluted tubules. There was staining in the endothelial cells of the glomeruli in some kidneys. Infrequent macrophages were stained. Endothelial cells of arteries and veins also stained. Staining was observed in the mucosa of the renal pelvis in the cytoplasm of the luminal cells in the transitional epithelium; this occurred in distinct segments. Within the renal pelvis, the transitional epithelium had an undulating appearance. The segments of transitional epithelium that appeared recessed, compared with the open cavity of the renal pelvis, stained throughout all cell layers, extending to but not including the lamina propria. The segments that were not recessed stained only along the membrane of the luminal cell layer or, in some segments, did not stain at all.
Immunohistochemical staining in ureter— Intense and uniform staining for uPA-like protein was detected along the luminal cell membranes of the surface epithelial cells and in the cytoplasm of all layers of transitional epithelial cells of the mucosal lining. The cytoplasm of infrequent macrophages in the connective tissue of the ureter wall and vascular endothelial cells stained as well.
Granular staining for uPAR-like protein was in the cytoplasm of the luminal and, sometimes, second layer of transitional epithelium. No staining was detected in the deeper cells of the transitional epithelium. There was staining of infrequent macrophages in the connective tissue of the ureter wall (Figure 3).
Immunohistochemical staining in urinary bladder—Variable staining for uPA-like protein was present in the transitional epithelium of the urinary bladder. Some segments of the mucosa stained throughout all cells in the luminal layer on both the cell membrane and in the cytoplasm. Other segments had staining only on the surface layer or not at all. The segments that had staining were often invaginated or depressed with respect to the luminal edge of the transitional epithelium, and there was increased vacuolization of the cytoplasm in the stained cells. There was also staining of the cytoplasm of smooth muscle cells and skeletal muscle cells, endothelial cells of vessels, and infrequent macrophages in the urinary bladder wall. Two of the urinary bladder sections had inflammation consistent with chronic cystitis and had intense uPA-like protein staining of the mucosa in the same segmental pattern as tissue samples with no evidence of inflammation. In the inflamed tissue, staining was more intense than in normal tissue. Staining was present in all cell layers of the transitional epithelium and was more intense in the invaginated segments.
Granular staining for uPAR-like protein was detected along the luminal surface of the transitional epithelium. Granular staining of the cytoplasm of these cells was evident in some regions, extending only to the first 1 to 2 layers of cells. Infrequent macrophages were detected in the urinary bladder wall and stained consistently.
Urethra—Consistent staining for uPA-like protein was evident in the transitional epithelium along the luminal border and in the cytoplasm of the cells extending all the way through the mucosa. This pattern of staining was similar to that observed in the urinary bladder mucosa in areas that had high numbers of cells with vacuolated cytoplasm and were invaginated. In other areas of the ureteral mucosa, the staining was only at the luminal surface, and some sections did not stain. There was staining in infrequent macrophages in the connective tissue of the urethral wall. There was no difference in the pattern of staining observed between the transitional epithelium of the prostatic and penile urethra of male dogs.
There was granular staining for uPAR-like protein of transitional epithelium of the ureter on the luminal surface of the cells and in the cytoplasm of the cells closest to the lumen. There was staining in the infrequent macrophages in the connective tissue of the urethral wall. In some sections, the staining was more intense in the cells of the transitional epithelium of the prostatic urethra than in the cells of the transitional epithelium of the penile urethra.
Prostate—Staining for uPA-like protein in the prostate was highly variable. Males 1 through 5 were sexually intact, and males 6 and 7 were neutered. Male 1 had a mature prostate and had variable faint staining in the cytoplasm of the connective tissue cells of glandular epithelium, but most glandular tissue did not stain. Epithelial cells lining the prostatic ducts did not stain. There was staining of infrequent macrophages in the connective tissue of the prostate. Male 2 had a mature prostate with some evidence of hyperplasia. Some faint staining of the cytoplasm of glandular cells was seen, but most of the glandular cells did not stain. Male 3 had a mature, hyperplastic prostate. Fixation of the tissue was not optimal, but there was faint staining of some glandular cells. Male 4 was a young dog, and the prostate had little acinar development. There was intense staining in the epithelial cells lining the developing ducts (Figure 3). Staining was less intense in epithelial cells of more differentiated ducts. There was staining of infrequent macrophages in the glandular connective tissue. Male 5 had a mature prostate with multiple hyperplastic and cystic regions. Epithelium in the ducts and glands of the cystic regions had moderate to intense staining. There was faint to no staining in the glandular cells of the hyperplastic regions. Male 6 had a normal prostate, and no staining was detected in glands or ducts, except for faint staining in the cytoplasm of a few foamy glandular prostatic cells. Male 7 had a hypoplastic prostate. There was staining in epithelial cells of the prostate glands and ducts, infrequent macrophages in the connective tissue, and endothelial cells of vessels. There was inconsistent but intense staining in the cytoplasm of epithelial cells lining primitive or poorly differentiated ducts.
There was no uPAR-like protein staining in most prostatic sections. There was staining of infrequent macrophages in the connective tissue, which acted as an internal control. Male 4 was young but sexually intact and had granular staining in the epithelial cells of the developing ducts at the apical surface and the cytoplasm (Figure 3). Staining was also detected in the epithelial cells of the more mature ducts at the apical borders. Staining intensity was equal to that in the less mature ducts. Intense staining was evident in interstitial resident macrophages. Male 7 was neutered and had a hypoplastic prostate. There was granular staining in the apical region of epithelial cells lining primitive or poorly developed ducts. There was staining of infrequent macrophages in the glandular connective tissue.
Testes—There was intense staining for uPA-like protein in all interstitial cells and seminiferous tubules, including all phases of spermatogonia. There was faint staining for uPAR-like protein in the cytoplasm of interstitial cells but no staining of seminiferous tubules or spermatogonia. There was staining of infrequent macrophages in the connective tissue.
Discussion
High–molecular-weight uPA and low–molecularweight uPA are 53 and 33 kd, respectively.21,22 The molecular weight of uPAR is more variable but usually is from 65 to 60 kd.5,23 These molecular weights were used as references for western blots to positively identify uPA-like and uPAR-like proteins in the study reported here. Immunoprecipitation concentrated the proteins and enhanced visualization of the protein bands in prostate and testis tissue lysates.
The canine kidneys had staining for uPA-like protein in the epithelium of all renal tubules and staining along the epithelial cells of the glomeruli in most specimens. Detection of uPA-like protein in the kidneys of the dogs studied was consistent with that reported for humans and mice.24–27 Immunohistochemical staining cannot be used to differentiate whether the antigen is present because of synthesis in the cells or because of binding to a receptor in or on the cell membrane. However, in vitro and in vivo studies24,27,28 of cell lines from human mesangial and tubule cells reveal that uPA is synthesized and secreted by glomerular visceral epithelial cells and kidney tubular epithelial cells. Given these findings in other mammalian species, the uPA-like protein in the renal tubules and glomeruli of the dogs reported here was likely synthesized there also. To verify this, cell culture studies would be required to verify secretion of uPA-like protein into the cell medium.
In the kidney, intense uPA-like protein staining was also detected along the transitional epithelium of the renal pelvis. Detection of uPA and associated fibri nolytic activity has been reported in epithelial cells of the renal calyces of humans.28,29 Urokinase is produced in the transitional epithelial cells in cattle but has not been investigated in other species.15 In the tubular structures of the urinary tract, uPA is important for maintaining patency during hemorrhage and fibrin deposition.30
Urokinase receptor staining is not detected in the kidneys of mice.31 This is consistent with findings in humans in which uPAR staining is not detected in the tubules of the kidneys of healthy donors.32 In another human study,33 glomerular cells in healthy kidney samples were not stained. In the dog kidneys of the present study, uPAR-like protein was detected along the basement membrane of renal tubular cells. This could indicate that in healthy dogs, kidneys produce uPAR-like protein, which would be different from humans. Many of the dogs in the present study had heartworm disease, indicated by microfilariae in glomeruli. This may have resulted in mild glomerulonephritis and increased production of uPAR-like protein. However, histopathologic evidence of glomerulonephritis was not detected. On the basis of our histologic findings, we believe that uPAR-like protein is present in the kidneys of healthy dogs. The role of uPAR-like protein and its sites of production cannot be determined without additional studies such as cell culture.
Transitional epithelium in the renal pelvis had staining for uPAR-like protein along the luminal surface and in the cytoplasm of luminal cells in the same regions as uPA-like protein staining. This may indicate that uPA-like protein is bound to uPAR at the cell surface or that uPA-like protein is produced in this tissue.
The pattern of uPA-like protein staining along the mucosal surfaces of the urinary tract was consistent among sections and sites. The ureter stained intensely, whereas staining in the urinary bladder and urethra was variable. The segments of transitional epithelium commonly stained were areas that appeared to be invaginated or depressed with respect to the lumen and had vacuolization in the cytoplasm of the stained cells. The importance of this finding was unknown. The stained regions may have indicated areas of uPA binding to cells that were damaged or being renewed, or these regions may have been indicative of uPA-producing cells in the transitional epithelium. Bovine urothelium produces uPA in culture medium.15
Urokinase receptor-like protein had a pattern of staining similar to that of uPA-like protein. It differed in that its appearance was granular and the staining was limited to the luminal surface and the cytoplasm of the first 1 to 2 layers of cells within the transitional epithelium. This pattern could indicate that uPA-like protein was produced and secreted by the deeper cells layers and then bound to the luminal layers by uPARlike protein. These luminal layers are rapidly shed and replenished in the urinary tract.
The variability of staining for uPA-like protein in the prostate tissue suggests the interesting possibility that production of uPA-like protein and uPAR-like protein may depend greatly on stage of development of the prostate. In rats, uPA production is influenced by hormones34–36 and is evident immunohistochemically in scattered cells at the surface of the epithelium facing the lumen of the glandular ducts. Staining is greater in castrated rats, which suggests a role for uPA in the involution of the prostate and normal turnover of prostate epithelium.36 Increased activity of plasminogen activators is detected via plasminogen activator assays in developing prostate tissue. This activity decreases when development is complete.34 This is consistent with the role of uPA and other plasminogen activators in tissue remodeling. This is supported by the findings of the present study in which staining of uPA-like protein and uPAR-like protein appeared to be limited to only developing ductile tissue. More specimens obtained at certain developmental stages are required to adequately characterize uPA-like protein and uPAR-like protein in the prostate of dogs.
Most prostate samples evaluated did not stain for uPAR-like protein. Male 4 was sexually intact, and staining was evident in the epithelial cells of the developing prostatic ducts and mature prostatic ducts at the apical surface and in the cytoplasm. Male 7 was neutered, but the prostate appeared hypoplastic or atrophied, suggesting that castration had been performed at a young age. Granular staining was detected around primitive or poorly developed ducts in the apical region. Staining for uPA-like protein and uPAR-like protein in the same regions indicated that uPA-like protein was either produced in these tissues or bound to the cells. It is possible, given the abundance of uPAlike protein in the other tissues of the urinary tract, that urokinase is truly bound at this site but produced elsewhere. Urokinase plasminogen activator-like protein and uPAR-like protein may contribute to tissue remodeling in the prostate of dogs. The importance of uPA and uPAR in development of the gland and involution after castration is evident in rat models of prostate development.35,37,38
Intense staining for uPA-like protein was seen in sections of testes in the seminiferous tubules and interstitial cells of dogs in the present study. This has been reported in rhesus monkeys and humans.39–41 Urokinase in the testes is believed to play a role during spermatogenesis and in spermatozoal motility. It has been suggested that infertility in some men may be attributable to low concentrations of uPA in the testes.41 Urokinase plasminogen activator receptor-like protein was not detected via staining in the seminiferous tubules of the dogs reported here. Staining was very weak in the cytoplasm of the interstitial cells. This observation differs from published data in rhesus monkeys and mice, in which uPAR was identified at high concentrations.40,42 Results of the western blot assays revealed that a uPAR-like protein was present in the canine testes. The low-degree staining of uPAR-like protein in the testes may have been caused by unavailability of the epitope on uPAR-like protein of dogs to which the monoclonal human uPAR antibody was directed. The uPAR-like protein in the testes may be so heavily bound with uPA-like protein that, unlike in the other tissue sections examined, it was masked in the testes. Urokinase plasminogen activator-like protein may also act in conjunction with another membrane-bound receptor, such as a low-density lipoprotein receptor,17 and not uPAR-like protein in the testes of dogs.
All urinary tract tissues examined had low numbers of macrophages that stained for uPA-like protein and uPAR-like protein. Macrophages secrete uPA and have uPAR on the cell membranes.43–46 Macrophages were interpreted as an internal control to verify that the staining protocol was working in tissues that otherwise had low levels of staining. Urokinase and uPAR play important roles in macrophage differentiation during inflammation and neoplasia and contribute to fibrosis, angiogenesis, and basement membrane degradation in affected tissues.17,46,47 The tissue sections from the urinary tract of all dogs in the present study had normal histologic features. The numbers of macrophages were typical for healthy urinary tract tissues, as judged on the basis of the experience of the pathologist (DBP) who evaluated the tissues. In the kidneys of healthy mice and mice with experimentally induced urinary tract obstruction, macrophages are in low numbers (< 5 cells/12 hpfs). Within 1 day of urinary obstruction, this number increases to a mean of 112.7 ± 20 cells/12 hpfs, which is a rapid increase in macrophage numbers in a short period.48 One would expect that in dogs with inflammation, infection, or neoplastic disease affecting the kidneys, much higher numbers of macrophages would have been present in the tissue sections examined. Because the kidney is not unique in its response to these types of diseases, it is expected that other tissues of the urinary tract would respond in similar ways with respect to migration of macrophages to sites of injury. The 2 sections of urinary bladder wall that had evidence of chronic cystitis had characteristic increases in neutrophils and macrophages, as would be expected with inflammation.
We hypothesized that urokinase would be present in the canine urinary tract on the basis of evidence of its presence in human studies; however, identification of urokinase in the canine urinary tract has not been reported. Cell types that stained for uPA-like protein and uPAR-like protein in the canine tissues were consistent with those described in humans, rats, monkeys, and mice in most instances.
Presently, there are no specific antibodies against canine urokinase. Selection of an antibody for identification of uPA-like protein in the canine urinary tract required consideration of any documentation of crossspecies use of that antibody. Various antigens have greater or lesser degrees of species specificity. At least 2 investigations15,49 have used a mouse anti-human monoclonal antibodyc to successfully detect urokinase in bovine urothelium and rat mammary tissue. A third investigation50 used a polyclonal goat anti-human uPA antibody to detect uPA in bovine endothelial cells. This cross-species reactivity suggests that at least some segment of the uPA protein structure is retained across some species, and our results suggest this includes dogs.
The use of an antibody directed against another species to identify uPA and uPAR in dogs could result in difficulty with background staining or target selectivity. However, because we were able to successfully use these antibodies in the immunoprecipitation, SDSPAGE, and western blot procedures, we believe that detection of uPA-like and uPAR-like proteins in the urinary tract of the healthy dogs was specific with the humanand mouse-targeted antibodies used.
Results of the study reported here indicated that uPA-like protein and uPAR-like protein were detectable in the tissues of the urinary tract of healthy dogs, but their role in maintenance of the healthy urinary tract is unknown. Many disease processes of the urinary tract have some degree of inflammation or infection associated with them. In humans, increased presence of uPAR occurs in such inflammatory processes. Increased presence of receptors would theoretically lead to increased binding of uPA and possibly trigger increased production of uPA that might enter the urine. Further studies are required to elucidate the role of uPA and uPAR in the pathophysiologic processes associated with urinary tract disease.
ABBREVIATIONS
uPA | Urokinase plasminogen activator |
uPAR | uPA receptor |
Myohanen H. Regulation of plasminogen activation. PhD thesis, Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland, 2003.
Mouse anti-mouse uPA, Molecular Innovations, Southfield, Mich.
Mouse anti-human uPA, American Diagnostica Inc, Standford, Conn.
Mouse anti-human uPAR, American Diagnostica Inc, Standford, Conn.
Peroxidase conjugated affinity-purified anti-mouse IgG, Rockland Immunochemicals Inc, Gilbertsville, Pa.
Thomas Dounce tissue grinder, Phoenix Equipment Inc, Rochester, NY.
Radioimmunoprecipitation solution, Sigma-Aldrich, St Louis, Mo.
Polypropylene tubes, Sarstedt AG & Co, Newton, NC.
SDS sample buffer, Novagen, Madison, Wis.
Perfect Protein HRP Western Blot molecular-weight marker, Novagen, Madison, Wis.
Rainbow Markers, Amersham Biosciences, Buckinghamshire, England.
BioTrace polyvinylidene fluoride, Pall Corp, Pensacola, Fla.
Bio Rad Mini Gel II, Bio-Rad Laboratories, Hercules, Calif.
Western Lightning Chemiluminescence Reagent, PerkinElmer Life Sciences, Boston, Mass.
Fuji Medical x-ray film, Super RX, Tokyo, Japan.
Protein G Plus/Protein A Agarose Suspension, Calbiochem, San Diego, Calif.
Proteinase K, Dako, Carpenteria, Calif.
EnVision+ System, HRP (DAB), Dako, Carpenteria, Calif.
Vector NovaRed substrate kit, Vector Labratories, Burlingame, Calif.
Target Retrieval Solution, High pH (pH, 9.9), Dako, Carpenteria, Calif.
References
- 1↑
Di Cera E, Krem MM. Serine proteases. Vol 2. London: Macmillan Publishers Ltd, Nature Publishing Group, 2003;1–9.
- 2↑
Spraggon G, Phillips C & Nowak UK, et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995;3:681–691.
- 3
Gellert GC, Goldfarb RH, Kitson RP. Physical association of uPAR with the alpha V integrin on the surface of human NK cells. Biochem Biophys Res Commun 2004;315:1025–1032.
- 4
Andreasen PA, Kjoller L & Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1–22.
- 5
Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002;3:932–943.
- 6
Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995;376:269–279.
- 7
Ray P, Bhatti R & Gadarowski J, et al. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer. Tumor Biol 1998;19:60–64.
- 8
Yoshida E, Ohmura S & Sugiki M, et al. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 1995;63:863–865.
- 9
Casella R, Shariat SF & Monoski MA, et al. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer 2002;95:2494–2499.
- 10
Darien BJ. Fibrinolytic system. In:Feldman BF, Zinkel JG, Jain NC, ed.Schalm's veterinary hematology. 5th ed.Philadelphia: Lippincott Williams & Wilkins, 2000;544–548.
- 11
Dubeau L, Jones PA & Rideout WM III, et al. Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium. Cancer Res 1988;48:5552–5556.
- 12
du Toit PJ, Van Aswegen CH, du Plessis DJ. The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells. Prostaglandins Leukot Essent Fatty Acids 1996;55:173–177.
- 13
Memarzadeh S, Kozak KR & Chang L, et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci U S A 2002;99:10647–10652.
- 14↑
Stump DC, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem 1986;261:12759–12766.
- 15↑
Deng FM, Ding M & Lavker RM, et al. Urothelial function reconsidered: a new role in urinary protein secretion. Proc Natl Acad Sci U S A 2001;98:154–159.
- 16
Repine T, Osswald M. Mennorrhea due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Clin Appl Thromb Hemost 1994;10:293–296.
- 17↑
Stepanova VV, Tkachuk VA. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 2002;67:109–118.
- 18
Florquin S, van den Berg JG & Olszyna DP, et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001;59:2054–2061.
- 19↑
Chavakis T, Kanse SM & May AE, et al. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem Soc Trans 2002;30:168–173.
- 20↑
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
- 21
Prewitt RM, Hoy C & Kong A, et al. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator. Am Rev Respir Dis 1990;141:290–295.
- 22
Schaller J, Nick H & Rickli EE, et al. Human low-molecular-weight urinary urokinase. Partial characterization and preliminary sequence data of two polypeptide chains. Eur J Biochem 1982;125:251–257.
- 23
Blasi F, Stoppelli MP, Cubellis MV. The receptor for urokinase-plasminogen activator. J Cell Biochem 1986;32:179–186.
- 24
Bequaj S, Shah AM, Ryan JM. Identification of cells responsible for urokinase-type plasminogen activator synthesis and secretion in human diploid kidney cell cultures. In Vitro Cell Dev Biol 2004;40:102–107.
- 25
Hayashi S, Yamada K. Presence of urokinase-converting protease in the cultured medium of human kidney cells. Nippon Ketsueki Gakkai Zasshi 1988;51:130–136.
- 26
Larsson LI, Skriver L & Nielsen LS, et al. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984;98:894–903.
- 27
Rondeau E, Ochi S & Lacave R, et al. Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 1989;36:593–600.
- 28
Andrassy K, Buchholz L & Bleyl U, et al. Topography of human urokinase activity in renal tissue. Nephron 1976;16:213–219.
- 29
Andrassy K, Ritz E. Isolation and renal localization of urokinase. In:Dubach UC, Schmidt U, ed.Proceedings of the International Symposium on the Biochemical Aspects of the Diagnostic Value of Urine. Bern, Switzerland: Hans Huber Publishers, 1979;330–341.
- 30↑
Kenichi M, Masanobu M & Takehiko K, et al. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. J Lab Clin Med 2004;144:69–77.
- 31↑
Xu Y, Hagege J & Mougenot B, et al. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 1996;50:2011–2019.
- 32↑
Roelofs JJ, Rowshani AT & van den Berg JG, et al. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 2003;64:1845–1853.
- 33↑
Tang W, Freiss H & di Mola FF, et al. Activation of the serine proteinase system in chronic kidney rejection. Transplantation 1998;65:1628–1634.
- 34↑
Wilson MJ, Sinha AA & Powell JE, et al. Plasminogen activator activities in the developing rat prostate. Biol Reprod 1988;38:723–731.
- 35
Wilson MJ, Ditmanson JD & Sinha AA, et al. Plasminogen activator activities in the ventral and dorsolateral prostatic lobes of aging Fischer 344 rats. Prostate 1990;16:147–161.
- 36↑
Andreasen PA, Kristensen P & Lund LR, et al. Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats. Endocrinology 1990;126:2567–2575.
- 37
Wilson MJ. Proteases in prostate development, function, and pathology. Microsc Res Tech 1995;30:305–318.
- 38
Wilson MJ, Norris H & Woodson M, et al. Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Cell Mol Biol Res 1995;41:603–612.
- 39
Zhang T, Guo CX & Hu ZY, et al. Localization of plasminogen activator and inhibitor, LH and androgen receptors and inhibin subunits in monkey epididymis. Mol Hum Reprod 1997;3:945–952.
- 40
Zhang T, Zhou HM, Liu YX. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes. Mol Hum Reprod 1997;3:223–231.
- 41↑
Huang X, Xia W & Xiong C, et al. Studies on the relationship between urokinase plasminogen activator (uPA) and human sperm motility. J Tongji Med Univ 1997;17:213–217.
- 42
Zhou H, Vassalli JD. The receptor for urokinase-type plasminogen activator is expressed during mouse spermatogenesis. FEBS Lett 1997;413:11–15.
- 43
Moriwaki H, Stempien-Otero A & Kremen M, et al. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004;95:637–644.
- 44
Pejler G, Winberg J & Vuong TT, et al. Secretion of macrophage urokinase plasminogen activator is dependent on proteoglycans. Eur J Biochem 2003;270:3971–3980.
- 45
Usher PA, Thomsen OF & Iverson P, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005;113:870–880.
- 46
Rao NK, Shi G, Chapman HA. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995;96:465–474.
- 47
Hildenbrand R, Dilger I & Horlin A, et al. Urokinase and macrophages n tumor angiogenesis. Br J Cancer 1995;72:818–823.
- 48↑
Lange-Sperandio B, Schimpgen K & Rodenbeck B, et al. Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int 2006;60:81–88.
- 49
Evans DM, Sloan-Stakleff KD. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis 1998–99;18:252–260.
- 50↑
Lee SW, Kahn ML, Dichek DA. Expression of an anchored urokinase in the apical endothelial cell membrane. J Biol Chem 1992;267:13020–13027.